CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
about
Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentImmune targeting of cancer stem cells in gastrointestinal oncologyBiomarkers and Targeted Therapy in Pancreatic CancerPancreatic cancer stem cells: emerging target for designing novel therapyCancer stem cells and drug resistance: the potential of nanomedicineTargeting CSC-related miRNAs for cancer therapy by natural agentsHuman correlates of provocative questions in pancreatic pathologyp-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signalingThe Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerA bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma.Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.Targeted drug delivery in pancreatic cancerExpression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic PancreatitisHead and neck cancer stem cells: the effect of HPV--an in vitro and mouse studyPancreatic cancer stem cells and EMT in drug resistance and metastasis.Tumor-initiating cells are enriched in CD44(hi) population in murine salivary gland tumor.New promising drug targets in cancer- and metastasis-initiating cells.Prostate cancer cell lines under hypoxia exhibit greater stem-like properties.PTEN loss accelerates KrasG12D-induced pancreatic cancer developmentTargeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeuticsNovel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.Increased expression of DNA repair genes in invasive human pancreatic cancer cells.Embryonic stem cell factors and pancreatic cancerCurrent immunotherapeutic approaches in pancreatic cancer.Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progressionNeoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44.The role of epithelial-mesenchymal transition in pancreatic cancerMolecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.Latexin exhibits tumor-suppressor potential in pancreatic ductal adenocarcinoma.Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer.A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluationEZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors
P2860
Q26740619-598B71C6-1844-4B6F-988F-39679C722F7BQ26749015-E6E4E044-E0B2-42C1-8D4B-A813B67462A0Q26752755-A47C54AB-770E-4582-B0D9-DBFC8105DC71Q26863365-4363665E-7518-4B72-A9DA-EB47E33A1690Q26998993-8597D010-E16D-4662-8F20-7C754F9AF6ACQ27003230-AB8A58D1-1C18-45A1-9B04-AC2EF554BEABQ27023576-CC990867-030E-43FA-94C9-AB660A233D5DQ28269527-B14878D6-4C8D-46C1-B163-A772841EB50CQ28468300-D79564AF-BD85-4127-9542-BB5D6606335FQ30557486-A1FA722A-70E8-452F-8999-6EFE7B6BCF29Q31098128-9FD21EEE-800A-4093-BABF-5A726E5B1E40Q33625651-55B6F6FD-75D0-4216-962E-BEBDC2B4F9EEQ33808976-A234C693-D1D9-497C-86F9-0969A5A7F99DQ33863903-41392538-63F2-4FE0-A1E3-3EE25109274CQ33886120-2BD23C74-F8C1-4A6B-8439-99A09C3656C7Q33999375-74800F01-8DF2-47BD-8A77-8A380C3EB4F7Q34003691-BD13A674-D767-4D25-997A-627FAD52B224Q34117287-CC03D3A9-4936-4F1D-8BCE-AD7867785C53Q34134396-02221423-F148-4D91-8163-5135895B975EQ34208986-D4511685-CB74-4280-98C8-B14BF5F00A89Q34218232-4614600C-CA47-4072-94EE-D0A96E9C610FQ34279411-30F63E75-E4FE-4762-B84F-397D0E9D2704Q34382586-C660842B-8139-470E-99B9-773509B615E7Q34456195-9EED59D4-178A-4B6C-847C-AA5C6363424FQ34861855-C5569975-E0B8-4E42-B966-7FF282C67ABAQ34874835-ED9006A9-772E-4353-AC2B-23DACB6F51B2Q35048189-5E26236E-4424-4DFC-B268-C510C0725C8BQ35113612-864A9DCF-F130-49B9-BD4D-604779284E3AQ35212837-79F0A4D3-BC21-435F-8390-984B5653FDA7Q35754181-E30319DC-44EB-4B4F-9FF9-355CC9F02C32Q36084344-3B6B7FAC-AB7F-40AB-AF87-0DB3F4E81693Q36097197-6270BA5D-C828-4EC5-88B5-E74FDC72D328Q36157197-86E32DAA-CA7B-44F3-A782-7225B2963CB1Q36425752-F8524BB9-7013-4CD6-8440-7038800C7F08Q36429978-933B00FE-052F-4136-9DEA-536073C9F628Q36537404-1355EA12-D304-4F3B-AE6C-8B6658FF8A4FQ36714052-1CB81826-F79F-445D-BCA8-5AA573873F3AQ36861707-75B81FDE-B9E6-4F65-9821-8878297BD6E1Q36979082-72EB83B0-DAC5-4A59-B8C4-3FC6504EC02FQ37017121-2086ABDA-15E9-4ED8-A6EE-FEAC738A1FB6
P2860
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
CD44-positive cells are respon ...... ce in pancreatic cancer cells.
@en
CD44-positive cells are respon ...... ce in pancreatic cancer cells.
@nl
type
label
CD44-positive cells are respon ...... ce in pancreatic cancer cells.
@en
CD44-positive cells are respon ...... ce in pancreatic cancer cells.
@nl
prefLabel
CD44-positive cells are respon ...... ce in pancreatic cancer cells.
@en
CD44-positive cells are respon ...... ce in pancreatic cancer cells.
@nl
P50
P356
P1476
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
@en
P2093
Sung Pil Hong
P304
P356
10.1002/IJC.24573
P577
2009-11-01T00:00:00Z